Expanded Newborn Bloodspot Screening: Developed Country Examples and What Can Be Done in Turkey

Overview

Journal Intractable Rare Dis Res

Date 2022 Jun 15

PMID 35702584

Authors

Caglar Fidan

Huseyin Orun

Asli Begum Alper

Cigdem Naz Unver

Omer Can Sahin

Zeynep Ugurlu

Recep Akdur

Domenica Taruscio

Affiliations

Soon will be listed here.

Abstract

Bloodspot screening in newborns is an exemplary public health intervention as it is essential secondary prevention with proven efficacy and benefit for the early diagnosis and prompt treatment of rare diseases. In this mini review, newborn bloodspot screening (NBS) programs of 12 countries were examined in terms of the extent of diseases/disorders screened to form recommendations for Turkey's expanded newborn screening program. Essentially, Turkey and 11 selected countries' official policies/ national programs or strategies in terms of newborn screening and the number of diseases/conditions screened were examined. The current status of spinal muscular atrophy (SMA) screening was also checked through the SMA NBS Alliance. In addition, WHO and EURORDIS guidelines for newborn screening were also reviewed. On the Pubmed database, following the search strategy "((newborn screening[Title/Abstract]) OR (newborn screening program[Title/Abstract])) OR (newborn blood spot screening[Title/Abstract])" in the PubMed database from 1 January 2008 to 1 December 2021. Diseases that will be recommended to be included in the Turkish national newborn bloodspot screening program will be presented by evaluating the updated criteria of Wilson and Jungner by constructing international comparisons. The number of diseases/disorders screened by the inspected 12 countries is eminently variable and ranges from 5 in Turkey to 51 in New York, United States of America (USA). Acknowledging the programs of other countries, it is evident that Turkey must advance its program by evaluating the epidemiological data in Turkey, the health workforce, and infrastructure while relying on the updated screening criteria. The newborn bloodspot screening program should be expanded based on the cost estimates and implemented starting with pilot applications and the diseases/disorders that are deemed appropriate should be included in the national program.

Citing Articles

Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century?.

Schnabel-Besson E, Mutze U, Dikow N, Horster F, Morath M, Alex K Int J Neonatal Screen. 2024; 10(3).

PMID: 39311364 PMC: 11417796. DOI: 10.3390/ijns10030062.

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).

Therrell B, Padilla C, Borrajo G, Khneisser I, Schielen P, Knight-Madden J Int J Neonatal Screen. 2024; 10(2).

PMID: 38920845 PMC: 11203842. DOI: 10.3390/ijns10020038.

An evaluation of untargeted metabolomics methods to characterize inborn errors of metabolism.

Wurth R, Turgeon C, Stander Z, Oglesbee D Mol Genet Metab. 2024; 141(1):108115.

PMID: 38181458 PMC: 10843816. DOI: 10.1016/j.ymgme.2023.108115.

Carrier screening programs for rare diseases in developed countries and the case of Turkey: A systematic review.

Fidan C, Akdur R, Unver C, Sahin O, Alper A, Ayhan A Intractable Rare Dis Res. 2023; 12(3):161-169.

PMID: 37662625 PMC: 10468408. DOI: 10.5582/irdr.2023.01005.

Identification of maternal attitudes and knowledge about newborn screenings: a Turkey sample.

Kadiroglu T, Altay G, Akay G, Can Bayrak C J Community Genet. 2023; 14(6):555-564.

PMID: 37535305 PMC: 10725403. DOI: 10.1007/s12687-023-00659-7.

References

Tiwana S, Rascati K, Park H . Cost-effectiveness of expanded newborn screening in Texas. Value Health. 2012; 15(5):613-21. DOI: 10.1016/j.jval.2012.02.007. View

Burgard P, Rupp K, Lindner M, Haege G, Rigter T, Weinreich S . Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis. 2012; 35(4):613-25. DOI: 10.1007/s10545-012-9484-z. View

Taruscio D, Kodra Y, Ferrari G, Vittozzi L . The Italian National Rare Diseases Registry. Blood Transfus. 2014; 12 Suppl 3:s606-13. PMC: 4044798. DOI: 10.2450/2014.0064-14s. View

Tezel B, Dilli D, Bolat H, Sahman H, Ozbas S, Acican D . The development and organization of newborn screening programs in Turkey. J Clin Lab Anal. 2013; 28(1):63-9. PMC: 6807568. DOI: 10.1002/jcla.21645. View

Andermann A, Blancquaert I, Beauchamp S, Dery V . Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008; 86(4):317-9. PMC: 2647421. DOI: 10.2471/blt.07.050112. View

Waters D, Adeloye D, Woolham D, Wastnedge E, Patel S, Rudan I . Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. J Glob Health. 2018; 8(2):021102. PMC: 6237105. DOI: 10.7189/jogh.08.021102. View

Tangeraas T, Saeves I, Klingenberg C, Jorgensen J, Kristensen E, Gunnarsdottir G . Performance of Expanded Newborn Screening in Norway Supported by Post-Analytical Bioinformatics Tools and Rapid Second-Tier DNA Analyses. Int J Neonatal Screen. 2020; 6(3):51. PMC: 7570219. DOI: 10.3390/ijns6030051. View

Landau Y, Waisbren S, Chan L, Levy H . Long-term outcome of expanded newborn screening at Boston children's hospital: benefits and challenges in defining true disease. J Inherit Metab Dis. 2017; 40(2):209-218. DOI: 10.1007/s10545-016-0004-4. View

Groft S, Posada de la Paz M . Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data. Adv Exp Med Biol. 2017; 1031:3-21. DOI: 10.1007/978-3-319-67144-4_1. View

10.

Loeber J, Burgard P, Cornel M, Rigter T, Weinreich S, Rupp K . Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis. 2012; 35(4):603-11. DOI: 10.1007/s10545-012-9483-0. View

11.

de Bitencourt F, Schwartz I, Vianna F . Infant mortality in Brazil attributable to inborn errors of metabolism associated with sudden death: a time-series study (2002-2014). BMC Pediatr. 2019; 19(1):52. PMC: 6367785. DOI: 10.1186/s12887-019-1421-y. View

12.

Balascakova M, Holubova A, Skalicka V, Zemkova D, Kracmar P, Gonsorcikova L . Pilot newborn screening project for cystic fibrosis in the Czech Republic: defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease. J Cyst Fibros. 2009; 8(3):224-7. DOI: 10.1016/j.jcf.2009.01.002. View

13.

Posset R, Gropman A, Nagamani S, Burrage L, Bedoyan J, Wong D . Impact of Diagnosis and Therapy on Cognitive Function in Urea Cycle Disorders. Ann Neurol. 2019; 86(1):116-128. PMC: 6692656. DOI: 10.1002/ana.25492. View

14.

Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab K, Tacke U . Efficacy and outcome of expanded newborn screening for metabolic diseases--report of 10 years from South-West Germany. Orphanet J Rare Dis. 2011; 6:44. PMC: 3141366. DOI: 10.1186/1750-1172-6-44. View

15.

Dobrow M, Hagens V, Chafe R, Sullivan T, Rabeneck L . Consolidated principles for screening based on a systematic review and consensus process. CMAJ. 2018; 190(14):E422-E429. PMC: 5893317. DOI: 10.1503/cmaj.171154. View

16.

Lund A, Wibrand F, Skogstrand K, Baekvad-Hansen M, Gregersen N, Andresen B . Use of Molecular Genetic Analyses in Danish Routine Newborn Screening. Int J Neonatal Screen. 2021; 7(3). PMC: 8395600. DOI: 10.3390/ijns7030050. View

17.

Armour C, Audibert F, Brock J, Brown R, Campagnolo C, Carroll J . Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing. J Obstet Gynaecol Can. 2016; 38(8):742-762.e3. DOI: 10.1016/j.jogc.2016.06.008. View

18.

Konstantopoulou V, Zeyda M . 25th Annual Meeting of the German Society of Newborn Screening. Int J Neonatal Screen. 2020; 4(2):17. PMC: 7510186. DOI: 10.3390/ijns4020017. View

19.

Loeber J, Platis D, Zetterstrom R, Almashanu S, Boemer F, Bonham J . Neonatal Screening in Europe Revisited: An ISNS Perspective on the Current State and Developments Since 2010. Int J Neonatal Screen. 2021; 7(1). PMC: 8006225. DOI: 10.3390/ijns7010015. View

20.

Castellani C, Massie J, Sontag M, Southern K . Newborn screening for cystic fibrosis. Lancet Respir Med. 2016; 4(8):653-661. DOI: 10.1016/S2213-2600(16)00053-9. View